Nanoplatforms as Solutions to Overcome Chemoresistance in Cancer Therapy
ACS Nano · 2026
DOI: 10.1021/acsnano.6c11091 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Nano, 2026. Verfasst von Wanyu Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medic…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Neoplasms, Antineoplastic Agents, Nanoparticles. Die Arbeit nennt 465 Literaturangaben. Gefördert von: National Key Research and Development Program of China, 1?3?5 Project for Disciplines of Excellent, West China Hospital, Sichuan University.
Abstract (Originalsprache)
Tumor chemoresistance, driven by mechanisms such as drug efflux, DNA repair, apoptosis inactivation, immunosuppressive microenvironments, and the maintenance of cancer stem cell (CSC) stemness, remains a major obstacle to effective chemotherapy and patient prognosis. Engineered nanoplatforms offer multifaceted strategies to overcome these barriers, including passive targeting, ligand-mediated active targeting, and membrane-mimetic camouflage for enhanced tumor accumulation. Stimuli-responsive and prodrug-based systems exploit tumor microenvironmental features, such as low pH, high glutathione, enzyme overexpression, and redox gradients, to achieve precise spatiotemporal drug release while avoiding efflux and inactivation. Codelivery of chemotherapeutics with sensitizers, immunotherapeutic agents, gene therapeutics, or physical stimuli enables synergistic intervention across multiple resistance pathways. Critically, CSC-targeted nanoplatforms selectively eliminate the root causes of tumor relapse and metastasis. By integrating targeted delivery, controlled release, multidrug synergy, and CSC elimination, nanotechnology platforms transform the management of chemoresistance from passive mitigation toward proactive prevention, offering a promising foundation for clinical translation and personalized cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for…
- Department of Pharmacy, West China Second University Hospital of Sichuan University, Chengdu610041, P. R. China.
- Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu610041, P. R. China.
- Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu610041, P. R. China.
- Children's Medicine Key Laboratory of Sichuan Province, West China Second University Hospital, Sichuan University, Chengdu, Sichuan610041, P. R. China.
ORCID-Profile: Fuming Liang, Xiang Gao
Förderung
- National Key Research and Development Program of China
- 1?3?5 Project for Disciplines of Excellent, West China Hospital, Sichuan University
Zitieren
APA
Wang, W., Liang, F., Zhang, L., & Gao, X. (2026). Nanoplatforms as Solutions to Overcome Chemoresistance in Cancer Therapy. ACS Nano. https://doi.org/10.1021/acsnano.6c11091
Vancouver
Wang W, Liang F, Zhang L, Gao X. Nanoplatforms as Solutions to Overcome Chemoresistance in Cancer Therapy. ACS Nano. 2026. doi:10.1021/acsnano.6c11091
BibTeX
@article{Wang2026,
author = {Wang, Wanyu and Liang, Fuming and Zhang, Lingli and Gao, Xiang},
title = {Nanoplatforms as Solutions to Overcome Chemoresistance in Cancer Therapy},
journal = {ACS Nano},
year = {2026},
doi = {10.1021/acsnano.6c11091}
}
EUVIMED